文献速递遗传性与小管间质肾病

ALDH1A1是治疗常染色体显性多囊肾病(ADPKD)的潜在新靶点

ALDH1A1 is a potential novel target for treatment of ADPKD.
PubMed 文献 · Kidney Int · 2026-01-01

该文评述Cheng等的研究,指出醛脱氢酶1A1(ALDH1A1)通过激活增殖通路和作为转录因子成为ADPKD的新风险因素;用双硫仑靶向ALDH1A1可延缓ADPKD小鼠囊肿生长,低剂量双硫仑联合抗PD-L1抗体协同减轻囊肿进展并改善免疫微环境。

要点

  • ALDH1A1通过激活增殖通路和转录因子作用促进ADPKD囊肿生长。
  • 双硫仑靶向ALDH1A1可延缓ADPKD小鼠的囊肿生长。
  • 低剂量双硫仑联合抗PD-L1抗体协同减轻囊肿进展并改善免疫微环境。

核心结论

  • ALDH1A1是ADPKD的潜在新风险因素和治疗靶点。
  • 重定位ALDH1A1抑制剂和PD-L1阻断可能成为ADPKD治疗新策略。

研究设计与样本

  • 本文为对Cheng等研究的评述,涉及ADPKD小鼠模型实验。

主要发现

  • ALDH1A1通过激活增殖通路和作为转录因子发挥作用。
  • 双硫仑靶向ALDH1A1可延缓ADPKD小鼠囊肿生长。
  • 低剂量双硫仑联合抗PD-L1抗体协同减轻囊肿进展并改善免疫微环境。

临床怎么用

  • 重定位ALDH1A1抑制剂和PD-L1阻断可能为ADPKD提供新治疗策略。

局限性

  • ALDH1A1在其他肾脏疾病中也上调,其转录机制需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cheng et al. identify aldehyde dehydrogenase 1A1 as a novel risk factor for autosomal dominant polycystic kidney disease, by both activating proliferative pathways and acting as a transcription factor. Targeting aldehyde dehydrogenase 1A1 with disulfiram delays cyst growth in autosomal dominant polycystic kidney disease mice. Combining low-dose disulfiram with anti-programmed death ligand 1 antibody synergistically attenuates cyst progression and improves the immune microenvironment. Although aldehyde dehydrogenase 1A1 upregulation occurs in other kidney diseases and its transcriptional mechanism warrants further study, repurposing aldehyde dehydrogenase 1A1 inhibitors and programmed death ligand 1 blockades may represent a novel strategy for autosomal dominant polycystic kidney disease therapy.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Zhang L, He JC. ALDH1A1 is a potential novel target for treatment of ADPKD. Kidney Int. 2026. PMID: 41864666. doi:10.1016/j.kint.2026.01.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。